Solid dispersions of niraparib or a pharmaceutically acceptable salt thereof
EP4762034A1Pending Publication Date: 2026-06-24ALIVUS LIFE SCIENCES LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- EP2024853962
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-14
- Filing Date
- 2024-08-14
- Publication Date
- 2026-06-24
AI Technical Summary
Technical Problem
Niraparib, a PARP inhibitor, exhibits poor solubility, which hampers the preparation of effective oral dosage forms, leading to reduced bioavailability and pharmacokinetic performance.
Method used
The development of solid dispersions comprising niraparib or its pharmaceutically acceptable salts with pharmaceutically acceptable carriers, such as polymers and non-polymeric porous materials, along with optional surfactants, to enhance solubility and bioavailability.
Benefits of technology
The solid dispersion approach significantly improves the solubility and bioavailability of niraparib, thereby enhancing its pharmacokinetic profile and therapeutic efficacy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure IMGF000002_0001 
Figure IMGF000012_0001 
Figure IMGF000015_0001
Abstract
The present invention relates to a solid dispersion comprising Niraparib or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention also relates to a process for the preparation of the solid dispersion, a pharmaceutical composition comprising the solid dispersion, and therapeutic use of the solid dispersion.
Need to check novelty before this filing date? Find Prior Art